Results from the HPTN Study 052 study show that initiation of antiretroviral treatment protects uninfected partners from HIV infection.

Mma Bana Study results published in The New England Journal of Medicine show that women taking ARVs can breastfeed with minimal risk of transmission of HIV/AIDS to their infants.

University of Botswana School of Medicine is awarded a Medical Education Partnership Initiative (MEPI) grant to partner with the BHP and University of Pennsylvania to train healthcare workers and improve medical education in Botswana.

Studies on early infections reveal subset of people most appropriate for targeted prevention studies.

Harvard President Drew Faust visits the BHP, the first visit of a sitting Harvard president to Africa. View slide show.

The Mochudi Prevention Project, a community-based HIV prevention study, begins enrollment.

KITSO trains its 5000th health care worker in Botswana.

BHP begins research programme to determine how human genetics influence risk for HIV infection and disease.

BHP becomes an independent, non-profit corporation.

Mashi Study results are published in The New England Journal of Medicine, showing best drug regimen for preventing mother-to-child transmission of HIV in resource poor settings while decreasing risk of drug resistance for mother.

“AIDS Action and Botswana: Lessons in Capacity Building and Importance of Research” conference held in Gaborone for government leaders from southern Africa.

Three Harvard undergrads participate in the first Semester Abroad program at BHP.

The BHP marks its10th anniversary.

The BHP Advisory Board, a group of Botswana leaders chaired by former Botswana President Masire, is formed to help identify and advise on immediate and long-term needs.

Dr. Joseph Makhema is named the new BHP Project Director.

BHP is selected as a Clinical Trials Unit (CTU) site by the U.S. N.I.H.

First results from the Mashi Study are presented at the 12th Conference on Retroviruses and Opportunistic Infections (CROI).

The Botswana-Harvard PEPFAR Program gets underway.

Enrollment opens for the Netefatso HIV Discordant Couples Study.

Enrollment opens for the Mma Bana Study to prevent mother-to-child HIV transmission among breastfeeding women.

A Memorandum of Agreement on Collaboration between the Harvard School of Public Health and the University of Botswana is signed.

The 11th HIV Vaccine Think Tank is held in Gaborone.

KITSO trains its 3000th health care worker in Botswana.

BHP helps in treating more than 11,000 HIV-infected patients in the Botswana national ARV treatment program.

The Ministry of Health and the Maiteko a Tshireletso Vaccine Initiative officially launch the first Phase I HIV Vaccine Trial, the first of its kind in southern Africa.

Local researchers successfully isolate HIV from patient specimens for the first time in Botswana at the HIV Reference Laboratory.

KITSO marks the training of 1000 health care workers in AIDS Clinical Care Fundamentals.

The first treatment site for Masa, Botswana’s national antiretroviral therapy programme, opens at the Infectious Disease Care Clinic at Princess Marina Hospital.

The Tshepo Study, the first large-scale clinical trial to investigate antiretroviral therapy in adults, begins.

The old BHP is renovated and re-opens as BHP’s HIV Vaccine Clinic.

The Botswana-Harvard HIV Reference Laboratory officially opens on World AIDS Day.

His Excellency President Festus Mogae receives the Harvard AIDS Institute’s Leadership Award for his contribution towards the fight against HIV/AIDS.

The Mashi Study officially opens in March at research sites in Molepolole, Mochudi and Lobatse.

Construction begins on the Botswana–Harvard HIV Reference Laboratory on the grounds of Princess Marina Hospital in Gaborone.

At the request of the Government of Botswana, the Ministry of Health and BHP establish the KITSO AIDS Training Program in response to the expanding HIV epidemic and the lack of continuing medical education available to health professionals.

The Second National HIV/AIDS Conference takes place.

The Mashi pilot study begins in Molepolole.

The first Botswana–Harvard Laboratory is officially opened by Minister of Health Joy Phumaphi.

Preparations begin for the Mashi Study to evaluate the effects of medication and breastfeeding on mother-to-infant transmission of HIV.

Dr. Ibou Thior arrives in Botswana from Senegal via Boston to serve as BHP Project Director.

BHP and the Ministry of Health co-host the National Conference on HIV/AIDS in Botswana.

BHP’s first study begins at Harvard, characterizing the molecular and biologic traits of HIV-1C.

President of Botswana Ketumile Masire meets with Harvard professor Max Essex in the U.S.

President Masire invites Essex to visit Botswana.
Discussions begin about an HIV research partnership.

Official agreement establishing Botswana–Harvard Partnership (BHP) is signed in October.